Fenwick Represents ACELYRIN in Pending Merger with Alumis

Fenwick is representing ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, in its pending merger with Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases.

The combined company will benefit from a differentiated late-stage portfolio of therapies and increased resources enabling the development of life-changing medicines. Together, the combined company will leverage its track record of R&D success, along with its proprietary data and analytics platform, which utilizes key genetic and translational insights to optimize outcomes to patients. More information can be obtained from the news announcement.

The Fenwick team includes corporate partners Ethan Skerry and Ryan Mitteness, counsel Jeremy Delman, associates Jordan Beals, Beth Clarke, John Batoha, Max Krinsky and Brian Honaker-Coe and law clerk Guy Rotstein; technology transactions partner Stefano Quintini, associates Jennifer Yoon, Kehl Sink, Phillip Yin, Rob Ferrari and Sam Dodson and advisor Sandra Weustink; executive compensation and employee benefits partners Gerald Audant and Elizabeth Gartland and associates Christophe Delrieu and Melita Chan; tax partner William Skinner and associate Alexis Maguina; antitrust and competition partner Mark Ostrau, counsel Meredith Mommers and associate Susan Lee; healthcare regulatory partner Jennifer Yoo and associate Stephanie Aldous; and privacy and cybersecurity counsel Melanie Jolson and associate Kayla Tanaka.